SELLAS Life Sciences Group Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SELLAS Life Sciences Group in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SELLAS Life Sciences Group stock.
View analyst ratings for SELLAS Life Sciences Group or view top-rated stocks.

Wall Street analysts have given SELLAS Life Sciences Group a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but SELLAS Life Sciences Group wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

SELLAS Life Sciences Group saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 1,130,000 shares, an increase of 28.9% from the June 30th total of 876,900 shares. Based on an average trading volume of 583,000 shares, the days-to-cover ratio is presently 1.9 days.
View SELLAS Life Sciences Group's Short Interest.

SELLAS Life Sciences Group is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for SELLAS Life Sciences Group.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) posted its quarterly earnings data on Thursday, May, 13th. The company reported ($0.16) earnings per share for the quarter. The firm had revenue of $5.70 million for the quarter.
View SELLAS Life Sciences Group's earnings history.

SELLAS Life Sciences Group's stock was trading at $2.14 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SLS stock has increased by 303.7% and is now trading at $8.64.
View which stocks have been most impacted by COVID-19.

Shares of SELLAS Life Sciences Group reverse split before market open on Friday, November 8th 2019. The 1-50 reverse split was announced on Wednesday, November 6th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 7th 2019. An investor that had 100 shares of SELLAS Life Sciences Group stock prior to the reverse split would have 2 shares after the split.

4 analysts have issued 12-month price targets for SELLAS Life Sciences Group's shares. Their forecasts range from $16.50 to $21.00. On average, they anticipate SELLAS Life Sciences Group's stock price to reach $18.38 in the next twelve months. This suggests a possible upside of 112.7% from the stock's current price.
View analysts' price targets for SELLAS Life Sciences Group or view top-rated stocks among Wall Street analysts.

Some companies that are related to SELLAS Life Sciences Group include Aldeyra Therapeutics (ALDX), Evelo Biosciences (EVLO), Greenwich LifeSciences (GLSI), VistaGen Therapeutics (VTGN), Inventiva (IVA), Clovis Oncology (CLVS), Vaccitech (VACC), Nanobiotix (NBTX), Clene (CLNN), KalVista Pharmaceuticals (KALV), Werewolf Therapeutics (HOWL), Basilea Pharmaceutica (BPMUF), ZIOPHARM Oncology (ZIOP), XBiotech (XBIT) and SIGA Technologies (SIGA).
View all of SLS's competitors.

SELLAS Life Sciences Group trades on the NASDAQ under the ticker symbol "SLS."

Shares of SLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SLS stock can currently be purchased for approximately $8.64.

SELLAS Life Sciences Group has a market capitalization of $130.33 million and generates $1.90 million in revenue each year. The company earns $-16,760,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis.

SELLAS Life Sciences Group employs 60 workers across the globe.

The official website for SELLAS Life Sciences Group is www.sellaslifesciences.com.

SELLAS Life Sciences Group is headquartered at 15 WEST 38TH STREET 10TH FLOOR, NEW YORK NY, 10018.

SELLAS Life Sciences Group's mailing address is 15 WEST 38TH STREET 10TH FLOOR, NEW YORK NY, 10018. The company can be reached via phone at (646) 200-5278 or via email at [email protected]